Medical Care
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Research Report 2024
- Jan 20, 24
- ID: 12759
- Pages: 90
- Figures: 188
- Views: 44
The global Squamous Non-Small Cell Lung Cancer Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Squamous Non-Small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Squamous Non-Small Cell Lung Cancer Therapeutics.
Report Scope
The Squamous Non-Small Cell Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Squamous Non-Small Cell Lung Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Squamous Non-Small Cell Lung Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Segment by Type
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Segment by Application
Research Center
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Squamous Non-Small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Squamous Non-Small Cell Lung Cancer Therapeutics.
Report Scope
The Squamous Non-Small Cell Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Squamous Non-Small Cell Lung Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Squamous Non-Small Cell Lung Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Segment by Type
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Segment by Application
Research Center
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 BMS-906024
1.2.3 Buparlisib Hydrochloride
1.2.4 FP-1039
1.2.5 Ipilimumab
1.2.6 JNJ-42756493
1.2.7 Lenvatinib
1.2.8 Others
1.3 Market by Application
1.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Research Center
1.3.3 Hospital
1.3.4 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Perspective (2019-2030)
2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Growth Trends by Region
2.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
2.3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
2.3.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
2.3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
2.3.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Revenue
3.1.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
3.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
3.5 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2025-2030)
5 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
6.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024)
6.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
7.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024)
7.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
9.2 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ascenta Therapeutics, Inc.
11.1.1 Ascenta Therapeutics, Inc. Company Detail
11.1.2 Ascenta Therapeutics, Inc. Business Overview
11.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.1.4 Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.1.5 Ascenta Therapeutics, Inc. Recent Development
11.2 AstraZeneca Plc
11.2.1 AstraZeneca Plc Company Detail
11.2.2 AstraZeneca Plc Business Overview
11.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.2.4 AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.2.5 AstraZeneca Plc Recent Development
11.3 AVEO Pharmaceuticals, Inc.
11.3.1 AVEO Pharmaceuticals, Inc. Company Detail
11.3.2 AVEO Pharmaceuticals, Inc. Business Overview
11.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.3.4 AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.3.5 AVEO Pharmaceuticals, Inc. Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Detail
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.4.4 Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.4.5 Bayer AG Recent Development
11.5 BIND Therapeutics, Inc.
11.5.1 BIND Therapeutics, Inc. Company Detail
11.5.2 BIND Therapeutics, Inc. Business Overview
11.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.5.4 BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.5.5 BIND Therapeutics, Inc. Recent Development
11.6 Boehringer Ingelheim GmbH
11.6.1 Boehringer Ingelheim GmbH Company Detail
11.6.2 Boehringer Ingelheim GmbH Business Overview
11.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.6.4 Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.6.5 Boehringer Ingelheim GmbH Recent Development
11.7 Bristol-Myers Squibb Company
11.7.1 Bristol-Myers Squibb Company Company Detail
11.7.2 Bristol-Myers Squibb Company Business Overview
11.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.7.4 Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.7.5 Bristol-Myers Squibb Company Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.8.4 Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.8.5 Eli Lilly and Company Recent Development
11.9 F. Hoffmann-La Roche Ltd.
11.9.1 F. Hoffmann-La Roche Ltd. Company Detail
11.9.2 F. Hoffmann-La Roche Ltd. Business Overview
11.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.9.4 F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
11.10 Five Prime Therapeutics, Inc.
11.10.1 Five Prime Therapeutics, Inc. Company Detail
11.10.2 Five Prime Therapeutics, Inc. Business Overview
11.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.10.4 Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.10.5 Five Prime Therapeutics, Inc. Recent Development
11.11 Genentech, Inc.
11.11.1 Genentech, Inc. Company Detail
11.11.2 Genentech, Inc. Business Overview
11.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.11.4 Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.11.5 Genentech, Inc. Recent Development
11.12 Incyte Corporation
11.12.1 Incyte Corporation Company Detail
11.12.2 Incyte Corporation Business Overview
11.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.12.4 Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.12.5 Incyte Corporation Recent Development
11.13 Johnson & Johnson
11.13.1 Johnson & Johnson Company Detail
11.13.2 Johnson & Johnson Business Overview
11.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.13.4 Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.13.5 Johnson & Johnson Recent Development
11.14 MacroGenics, Inc.
11.14.1 MacroGenics, Inc. Company Detail
11.14.2 MacroGenics, Inc. Business Overview
11.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.14.4 MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.14.5 MacroGenics, Inc. Recent Development
11.15 Novartis AG
11.15.1 Novartis AG Company Detail
11.15.2 Novartis AG Business Overview
11.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.15.4 Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.15.5 Novartis AG Recent Development
11.16 Oncogenex Pharmaceuticals, Inc.
11.16.1 Oncogenex Pharmaceuticals, Inc. Company Detail
11.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
11.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.16.4 Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.16.5 Oncogenex Pharmaceuticals, Inc. Recent Development
11.17 PsiOxus Therapeutics Limited
11.17.1 PsiOxus Therapeutics Limited Company Detail
11.17.2 PsiOxus Therapeutics Limited Business Overview
11.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.17.4 PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.17.5 PsiOxus Therapeutics Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 BMS-906024
1.2.3 Buparlisib Hydrochloride
1.2.4 FP-1039
1.2.5 Ipilimumab
1.2.6 JNJ-42756493
1.2.7 Lenvatinib
1.2.8 Others
1.3 Market by Application
1.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Research Center
1.3.3 Hospital
1.3.4 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Perspective (2019-2030)
2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Growth Trends by Region
2.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
2.3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
2.3.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
2.3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
2.3.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Revenue
3.1.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue
3.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
3.5 Squamous Non-Small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2025-2030)
5 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
6.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024)
6.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
7.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024)
7.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
9.2 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ascenta Therapeutics, Inc.
11.1.1 Ascenta Therapeutics, Inc. Company Detail
11.1.2 Ascenta Therapeutics, Inc. Business Overview
11.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.1.4 Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.1.5 Ascenta Therapeutics, Inc. Recent Development
11.2 AstraZeneca Plc
11.2.1 AstraZeneca Plc Company Detail
11.2.2 AstraZeneca Plc Business Overview
11.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.2.4 AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.2.5 AstraZeneca Plc Recent Development
11.3 AVEO Pharmaceuticals, Inc.
11.3.1 AVEO Pharmaceuticals, Inc. Company Detail
11.3.2 AVEO Pharmaceuticals, Inc. Business Overview
11.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.3.4 AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.3.5 AVEO Pharmaceuticals, Inc. Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Detail
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.4.4 Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.4.5 Bayer AG Recent Development
11.5 BIND Therapeutics, Inc.
11.5.1 BIND Therapeutics, Inc. Company Detail
11.5.2 BIND Therapeutics, Inc. Business Overview
11.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.5.4 BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.5.5 BIND Therapeutics, Inc. Recent Development
11.6 Boehringer Ingelheim GmbH
11.6.1 Boehringer Ingelheim GmbH Company Detail
11.6.2 Boehringer Ingelheim GmbH Business Overview
11.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.6.4 Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.6.5 Boehringer Ingelheim GmbH Recent Development
11.7 Bristol-Myers Squibb Company
11.7.1 Bristol-Myers Squibb Company Company Detail
11.7.2 Bristol-Myers Squibb Company Business Overview
11.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.7.4 Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.7.5 Bristol-Myers Squibb Company Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.8.4 Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.8.5 Eli Lilly and Company Recent Development
11.9 F. Hoffmann-La Roche Ltd.
11.9.1 F. Hoffmann-La Roche Ltd. Company Detail
11.9.2 F. Hoffmann-La Roche Ltd. Business Overview
11.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.9.4 F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
11.10 Five Prime Therapeutics, Inc.
11.10.1 Five Prime Therapeutics, Inc. Company Detail
11.10.2 Five Prime Therapeutics, Inc. Business Overview
11.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.10.4 Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.10.5 Five Prime Therapeutics, Inc. Recent Development
11.11 Genentech, Inc.
11.11.1 Genentech, Inc. Company Detail
11.11.2 Genentech, Inc. Business Overview
11.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.11.4 Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.11.5 Genentech, Inc. Recent Development
11.12 Incyte Corporation
11.12.1 Incyte Corporation Company Detail
11.12.2 Incyte Corporation Business Overview
11.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.12.4 Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.12.5 Incyte Corporation Recent Development
11.13 Johnson & Johnson
11.13.1 Johnson & Johnson Company Detail
11.13.2 Johnson & Johnson Business Overview
11.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.13.4 Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.13.5 Johnson & Johnson Recent Development
11.14 MacroGenics, Inc.
11.14.1 MacroGenics, Inc. Company Detail
11.14.2 MacroGenics, Inc. Business Overview
11.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.14.4 MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.14.5 MacroGenics, Inc. Recent Development
11.15 Novartis AG
11.15.1 Novartis AG Company Detail
11.15.2 Novartis AG Business Overview
11.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.15.4 Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.15.5 Novartis AG Recent Development
11.16 Oncogenex Pharmaceuticals, Inc.
11.16.1 Oncogenex Pharmaceuticals, Inc. Company Detail
11.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
11.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.16.4 Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.16.5 Oncogenex Pharmaceuticals, Inc. Recent Development
11.17 PsiOxus Therapeutics Limited
11.17.1 PsiOxus Therapeutics Limited Company Detail
11.17.2 PsiOxus Therapeutics Limited Business Overview
11.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
11.17.4 PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
11.17.5 PsiOxus Therapeutics Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of BMS-906024
Table 3. Key Players of Buparlisib Hydrochloride
Table 4. Key Players of FP-1039
Table 5. Key Players of Ipilimumab
Table 6. Key Players of JNJ-42756493
Table 7. Key Players of Lenvatinib
Table 8. Key Players of Others
Table 9. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2019-2024)
Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2025-2030)
Table 15. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
Table 16. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
Table 17. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
Table 18. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
Table 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players (2019-2024)
Table 21. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2023)
Table 22. Ranking of Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
Table 26. Date of Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2019-2024)
Table 30. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2025-2030)
Table 32. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2019-2024)
Table 34. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2025-2030)
Table 36. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 51. Ascenta Therapeutics, Inc. Company Detail
Table 52. Ascenta Therapeutics, Inc. Business Overview
Table 53. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 54. Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 55. Ascenta Therapeutics, Inc. Recent Development
Table 56. AstraZeneca Plc Company Detail
Table 57. AstraZeneca Plc Business Overview
Table 58. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 59. AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 60. AstraZeneca Plc Recent Development
Table 61. AVEO Pharmaceuticals, Inc. Company Detail
Table 62. AVEO Pharmaceuticals, Inc. Business Overview
Table 63. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 64. AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 65. AVEO Pharmaceuticals, Inc. Recent Development
Table 66. Bayer AG Company Detail
Table 67. Bayer AG Business Overview
Table 68. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 69. Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 70. Bayer AG Recent Development
Table 71. BIND Therapeutics, Inc. Company Detail
Table 72. BIND Therapeutics, Inc. Business Overview
Table 73. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 74. BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 75. BIND Therapeutics, Inc. Recent Development
Table 76. Boehringer Ingelheim GmbH Company Detail
Table 77. Boehringer Ingelheim GmbH Business Overview
Table 78. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 79. Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 80. Boehringer Ingelheim GmbH Recent Development
Table 81. Bristol-Myers Squibb Company Company Detail
Table 82. Bristol-Myers Squibb Company Business Overview
Table 83. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 84. Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 85. Bristol-Myers Squibb Company Recent Development
Table 86. Eli Lilly and Company Company Detail
Table 87. Eli Lilly and Company Business Overview
Table 88. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 89. Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 90. Eli Lilly and Company Recent Development
Table 91. F. Hoffmann-La Roche Ltd. Company Detail
Table 92. F. Hoffmann-La Roche Ltd. Business Overview
Table 93. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 94. F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 95. F. Hoffmann-La Roche Ltd. Recent Development
Table 96. Five Prime Therapeutics, Inc. Company Detail
Table 97. Five Prime Therapeutics, Inc. Business Overview
Table 98. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 99. Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 100. Five Prime Therapeutics, Inc. Recent Development
Table 101. Genentech, Inc. Company Detail
Table 102. Genentech, Inc. Business Overview
Table 103. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 104. Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 105. Genentech, Inc. Recent Development
Table 106. Incyte Corporation Company Detail
Table 107. Incyte Corporation Business Overview
Table 108. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 109. Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 110. Incyte Corporation Recent Development
Table 111. Johnson & Johnson Company Detail
Table 112. Johnson & Johnson Business Overview
Table 113. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 114. Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 115. Johnson & Johnson Recent Development
Table 116. MacroGenics, Inc. Company Detail
Table 117. MacroGenics, Inc. Business Overview
Table 118. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 119. MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 120. MacroGenics, Inc. Recent Development
Table 121. Novartis AG Company Detail
Table 122. Novartis AG Business Overview
Table 123. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 124. Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 125. Novartis AG Recent Development
Table 126. Oncogenex Pharmaceuticals, Inc. Company Detail
Table 127. Oncogenex Pharmaceuticals, Inc. Business Overview
Table 128. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 129. Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 130. Oncogenex Pharmaceuticals, Inc. Recent Development
Table 131. PsiOxus Therapeutics Limited Company Detail
Table 132. PsiOxus Therapeutics Limited Business Overview
Table 133. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 134. PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 135. PsiOxus Therapeutics Limited Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. BMS-906024 Features
Figure 4. Buparlisib Hydrochloride Features
Figure 5. FP-1039 Features
Figure 6. Ipilimumab Features
Figure 7. JNJ-42756493 Features
Figure 8. Lenvatinib Features
Figure 9. Others Features
Figure 10. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application: 2023 VS 2030
Figure 12. Research Center Case Studies
Figure 13. Hospital Case Studies
Figure 14. Clinic Case Studies
Figure 15. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region: 2023 VS 2030
Figure 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players in 2023
Figure 20. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
Figure 22. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
Figure 24. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
Figure 28. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2019-2030)
Figure 36. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
Figure 44. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
Figure 48. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Ascenta Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 51. AstraZeneca Plc Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 52. AVEO Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 53. Bayer AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 54. BIND Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 55. Boehringer Ingelheim GmbH Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 56. Bristol-Myers Squibb Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 57. Eli Lilly and Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 58. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 59. Five Prime Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 60. Genentech, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 61. Incyte Corporation Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 62. Johnson & Johnson Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 63. MacroGenics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 64. Novartis AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 65. Oncogenex Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 66. PsiOxus Therapeutics Limited Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Table 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of BMS-906024
Table 3. Key Players of Buparlisib Hydrochloride
Table 4. Key Players of FP-1039
Table 5. Key Players of Ipilimumab
Table 6. Key Players of JNJ-42756493
Table 7. Key Players of Lenvatinib
Table 8. Key Players of Others
Table 9. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2019-2024)
Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2025-2030)
Table 15. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
Table 16. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
Table 17. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
Table 18. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
Table 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players (2019-2024)
Table 21. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2023)
Table 22. Ranking of Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Squamous Non-Small Cell Lung Cancer Therapeutics Product Solution and Service
Table 26. Date of Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2019-2024)
Table 30. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2025-2030)
Table 32. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2019-2024)
Table 34. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2025-2030)
Table 36. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 51. Ascenta Therapeutics, Inc. Company Detail
Table 52. Ascenta Therapeutics, Inc. Business Overview
Table 53. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 54. Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 55. Ascenta Therapeutics, Inc. Recent Development
Table 56. AstraZeneca Plc Company Detail
Table 57. AstraZeneca Plc Business Overview
Table 58. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 59. AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 60. AstraZeneca Plc Recent Development
Table 61. AVEO Pharmaceuticals, Inc. Company Detail
Table 62. AVEO Pharmaceuticals, Inc. Business Overview
Table 63. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 64. AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 65. AVEO Pharmaceuticals, Inc. Recent Development
Table 66. Bayer AG Company Detail
Table 67. Bayer AG Business Overview
Table 68. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 69. Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 70. Bayer AG Recent Development
Table 71. BIND Therapeutics, Inc. Company Detail
Table 72. BIND Therapeutics, Inc. Business Overview
Table 73. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 74. BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 75. BIND Therapeutics, Inc. Recent Development
Table 76. Boehringer Ingelheim GmbH Company Detail
Table 77. Boehringer Ingelheim GmbH Business Overview
Table 78. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 79. Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 80. Boehringer Ingelheim GmbH Recent Development
Table 81. Bristol-Myers Squibb Company Company Detail
Table 82. Bristol-Myers Squibb Company Business Overview
Table 83. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 84. Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 85. Bristol-Myers Squibb Company Recent Development
Table 86. Eli Lilly and Company Company Detail
Table 87. Eli Lilly and Company Business Overview
Table 88. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 89. Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 90. Eli Lilly and Company Recent Development
Table 91. F. Hoffmann-La Roche Ltd. Company Detail
Table 92. F. Hoffmann-La Roche Ltd. Business Overview
Table 93. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 94. F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 95. F. Hoffmann-La Roche Ltd. Recent Development
Table 96. Five Prime Therapeutics, Inc. Company Detail
Table 97. Five Prime Therapeutics, Inc. Business Overview
Table 98. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 99. Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 100. Five Prime Therapeutics, Inc. Recent Development
Table 101. Genentech, Inc. Company Detail
Table 102. Genentech, Inc. Business Overview
Table 103. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 104. Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 105. Genentech, Inc. Recent Development
Table 106. Incyte Corporation Company Detail
Table 107. Incyte Corporation Business Overview
Table 108. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 109. Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 110. Incyte Corporation Recent Development
Table 111. Johnson & Johnson Company Detail
Table 112. Johnson & Johnson Business Overview
Table 113. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 114. Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 115. Johnson & Johnson Recent Development
Table 116. MacroGenics, Inc. Company Detail
Table 117. MacroGenics, Inc. Business Overview
Table 118. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 119. MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 120. MacroGenics, Inc. Recent Development
Table 121. Novartis AG Company Detail
Table 122. Novartis AG Business Overview
Table 123. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 124. Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 125. Novartis AG Recent Development
Table 126. Oncogenex Pharmaceuticals, Inc. Company Detail
Table 127. Oncogenex Pharmaceuticals, Inc. Business Overview
Table 128. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 129. Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 130. Oncogenex Pharmaceuticals, Inc. Recent Development
Table 131. PsiOxus Therapeutics Limited Company Detail
Table 132. PsiOxus Therapeutics Limited Business Overview
Table 133. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 134. PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 135. PsiOxus Therapeutics Limited Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. BMS-906024 Features
Figure 4. Buparlisib Hydrochloride Features
Figure 5. FP-1039 Features
Figure 6. Ipilimumab Features
Figure 7. JNJ-42756493 Features
Figure 8. Lenvatinib Features
Figure 9. Others Features
Figure 10. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application: 2023 VS 2030
Figure 12. Research Center Case Studies
Figure 13. Hospital Case Studies
Figure 14. Clinic Case Studies
Figure 15. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region: 2023 VS 2030
Figure 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players in 2023
Figure 20. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
Figure 22. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
Figure 24. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
Figure 28. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2019-2030)
Figure 36. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
Figure 44. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2019-2030)
Figure 48. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Ascenta Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 51. AstraZeneca Plc Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 52. AVEO Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 53. Bayer AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 54. BIND Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 55. Boehringer Ingelheim GmbH Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 56. Bristol-Myers Squibb Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 57. Eli Lilly and Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 58. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 59. Five Prime Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 60. Genentech, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 61. Incyte Corporation Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 62. Johnson & Johnson Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 63. MacroGenics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 64. Novartis AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 65. Oncogenex Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 66. PsiOxus Therapeutics Limited Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232